Sequencing therapy for advanced renal cancer
Mené dans 12 pays sur 350 patients atteints d'un carcinome à cellules rénales de stade métastatique, cet essai de phase III compare l'efficacité, du point de vue de la survie sans progression, et la toxicité du tivozanib et du sorafénib en traitement de troisième ou de quatrième ligne (durée médiane de suivi : 19 mois)
In The Lancet Oncology, Brian Rini and colleagues report the results of TIVO-3, a phase 3, multicentre, randomised, controlled, open-label trial comparing tivozanib, a selective VEGF receptor (VEGFR) tyrosine kinase inhibitor, with sorafenib, an earlier-generation tyrosine kinase inhibitor, as third-line or fourth-line therapy in patients with advanced, clear-cell, renal cell carcinoma. Tivozanib inhibits VEGFR1, VEGFR2, and VEGFR3, similar to axitinib, a drug previously compared with sorafenib as second-line therapy in mostly patients who progressed after VEGFR tyrosine kinase inhibitor or cytokine treatment. Progression-free survival in that study was 6·7 months with axitinib compared with 4·7 months with sorafenib (HR 0·66, 95% CI 0·54–0·81; p<0·0001). Patients had fewer lines of therapy than those in the study by Rini and colleagues, and no overall survival benefit was observed for axitinib.
The Lancet Oncology , commentaire, 2018